Abstract: Methods of detecting nucleic acids, including methods of detecting two or more nucleic acids in multiplex branched-chain DNA assays, are provided. Nucleic acids captured on a solid support are detected, for example, through cooperative hybridization events that result in specific association of a label with the nucleic acids. Compositions, kits, and systems related to the methods are also described.

Abstract: Methods of detecting nucleic acids, including methods of detecting two or more nucleic acids in multiplex branched-chain DNA assays, are provided. Nucleic acids captured on a solid support are detected, for example, through cooperative hybridization events that result in specific association of a label with the nucleic acids. Compositions, kits, and systems related to the methods are also described.

Abstract: Methods of detecting nucleic acids, including methods of detecting two or more nucleic acids in multiplex branched-chain DNA assays, are provided. Nucleic acids captured on a solid support are detected, for example, through cooperative hybridization events that result in specific association of a label with the nucleic acids. Compositions, kits, and systems related to the methods are also described.

Abstract: Methods of detecting various types of nucleic acids, including methods of detecting two or more nucleic acids in multiplex branched-chain DNA assays, are provided. Detection assays may be conducted at least in vitro, in cellulo, and in situ. Nucleic acids which are optionally captured on a solid support are detected, for example, through cooperative hybridization events that result in specific association of a label probe system with the nucleic acids. Various label probe system embodiments are provided. Compositions, kits, and systems related to the methods are also described.

Abstract: Methods of detecting various types of nucleic acids, including methods of detecting two or more nucleic acids in multiplex branched-chain DNA assays, are provided. Detection assays may be conducted at least in vitro, in cellulo, and in situ. Nucleic acids which are optionally captured on a solid support are detected, for example, through cooperative hybridization events that result in specific association of a label probe system with the nucleic acids. Various label probe system embodiments are provided. Compositions, kits, and systems related to the methods are also described.

Abstract: Devices, systems and methods for separation of magnetic particles with either hand held devices or automated instruments. Specifically, the production of magnetic fields for the separation of the particles within containers such as microtiter plates with a magnetic field that is substantially consistent for each well. Certain embodiments produce a magnetic field that is substantially uniform across each well bottom, while other embodiments produce a magnetic field that is stronger toward the outer region of each well.

Abstract: Methods of detecting nucleic acids, including methods of detecting two or more nucleic acids in multiplex branched-chain DNA assays, are provided. Nucleic acids captured on a solid support are detected, for example, through cooperative hybridization events that result in specific association of a label with the nucleic acids. Compositions, kits, and systems related to the methods are also described.

Abstract: Methods of detecting nucleic acids, including methods of detecting two or more nucleic acids in multiplex branched-chain DNA assays, are provided. Nucleic acids captured on a solid support are detected, for example, through cooperative hybridization events that result in specific association of a label with the nucleic acids. Compositions, kits, and systems related to the methods are also described.

Abstract: Methods of detecting nucleic acids, including methods of detecting two or more nucleic acids in multiplex branched-chain DNA assays, are provided. Nucleic acids captured on a solid support are detected, for example, through cooperative hybridization events that result in specific association of a label with the nucleic acids. Compositions, kits, and systems related to the methods are also described.

Abstract: Methods of detecting nucleic acids, including methods of detecting two or more nucleic acids in multiplex branched-chain DNA assays, are provided. Nucleic acids captured on a solid support are detected, for example, through cooperative hybridization events that result in specific association of a label with the nucleic acids. Compositions, kits, and systems related to the methods are also described.

Abstract: The invention provides isolated nucleic acids that encode RGL3, and fragments thereof, vectors for propagating and expressing RGL3 nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel RGL3 isoforms, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising human RGL3 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human RGL3 gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the RGL3 nucleic acids, proteins, and antibodies of the present invention.

Abstract: The invention provides isolated nucleic acids that encode MDZ3, MDZ4, MDZ7 and MDZ12, and fragments thereof, vectors for propagating and expressing MDZ3, MDZ4, MDZ7 and MDZ12 nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel MDZ3, MDZ4, MDZ7 and MDZ12 isoforms, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising human MDZ3, MDZ4, MDZ7 and MDZ12 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human MDZ3, MDZ4, MDZ7 or MDZ12 gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the MDZ3, MDZ4, MDZ7 or MDZ12 nucleic acids, proteins, and antibodies of the present invention.

Abstract: The invention provides isolated nucleic acids that encode human pp-GaNTase 10, and fragments thereof, vectors for propagating and expressing human pp-GaNTase 10 nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel human pp-GaNTase 10 isoforms, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising human pp-GaNTase 10 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human pp-GaNTase 10 gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the human pp-GaNTase 10 nucleic acids, proteins, and antibodies of the present invention.

Abstract: The invention provides isolated nucleic acids that encode RGL3, and fragments thereof, vectors for propagating and expressing RGL3 nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel RGL3 isoforms, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising human RGL3 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human RGL3 gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the RGL3 nucleic acids, proteins, and antibodies of the present invention.

Abstract: The invention provides isolated nucleic acids that encode LCP, including two isoforms, and fragments thereof, vectors for propagating and expressing LCP nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel LCP isoforms, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising human LCP nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human LCP gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the LCP nucleic acids, proteins, and antibodies of the present invention.

Abstract: The invention provides isolated nucleic acids that encode a human protein kinase domain-containing portein (STTK), and fragments thereof, vectors for propagating and expressing STTK nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel STTK isoforms, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising STTK nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the STTK gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the STTK nucleic acids, proteins, and antibodies of the present invention.